Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/6/2025

Treatment of Obsessive-Compulsive Disorder (OCD)

Introduction to Treatment

  • The American College of Neurology and Psychiatry recommends SSRIs (Selective Serotonin Reuptake Inhibitors) as the primary pharmacological intervention with strong evidence supporting their efficacy, requiring higher doses than those used for depression or anxiety disorders, and a treatment duration of 8-12 weeks to determine efficacy, with maintenance treatment continuing for at least 12-24 months after achieving remission 1
  • Cognitive-Behavioral Therapy (CBT) with exposure and response prevention (ERP) is the psychological treatment of choice for OCD, with meta-analyses showing CBT has larger effect sizes than pharmacological therapy, and can be delivered individually or in groups, in-person or via internet-based protocols, with patient adherence to between-session homework being the strongest predictor of good outcomes 1

First-Line Treatments

  • SSRIs are recommended as the first-line pharmacological treatment for OCD, with guidelines from various societies supporting their use 1
  • Cognitive-behavioral therapy (CBT) with exposure and response prevention is also a recommended first-line treatment for OCD 1

Second-Line Treatments

  • For patients who don't respond adequately to first-line treatments, switching to a different SSRI or using higher doses is recommended, with the goal of achieving optimal treatment outcomes 1
  • Combining SSRIs with CBT shows larger effect sizes than other augmentation strategies, and is a recommended approach for patients with partial response to first-line treatments 1
  • Augmentation with antipsychotics, particularly risperidone and aripiprazole, is a recommended approach for patients with partial response to first-line treatments 1
  • Augmentation with clomipramine, a tricyclic antidepressant with strong serotonergic effects, is a recommended approach for patients with partial response to first-line treatments, but requires careful monitoring due to the risk of severe adverse events including seizures, heart arrhythmia, and serotonin syndrome 1
  • Glutamatergic agents, such as N-acetylcysteine, have the strongest evidence base among these agents, and may be considered for patients with treatment-resistant OCD, with three out of five randomized controlled trials demonstrating superiority to placebo 1

Treatment Resistance

  • For truly treatment-resistant OCD that has not responded to multiple evidence-based approaches, neuromodulation techniques may be considered rather than medications without established efficacy 1
  • Approximately half of OCD patients fail to fully respond to first-line treatments, highlighting the need for second-line and adjunctive therapies 1

Adverse Effects

  • Clonidine has significant side effects, including somnolence, fatigue, hypotension, and irritability, which should be considered when evaluating its potential use in OCD treatment, although it is not recommended as a first-line or second-line treatment for OCD due to insufficient evidence supporting its efficacy for this condition 2, 1
  • Clomipramine requires careful monitoring when used with SSRIs due to the risk of severe adverse events including seizures, heart arrhythmia, and serotonin syndrome 1
  • N-acetylcysteine is generally well-tolerated, but may have adverse effects, although the evidence base for its use in OCD is stronger than other glutamatergic agents 1